IP Library › Granted Patent US 12,440,445
Granted Patent B2
US 12,440,445 · App. 17/658,078 · Granted Oct 14, 2025

Fusogenic compounds for delivery of biologically active molecules

Inventors: Kwok Yin Tsang (Irvine, CA); Bharat Majeti (San Diego, CA); John Gaudette (Poway, CA); Roger Adami (Carlsbad, CA); Hao Bai (San Diego, CA); Wenbin Ying (San Diego, CA)
Assignee: Nitto Denko Corporation
A61K9/1272A61K31/7105A61K47/10A61K47/14A61K47/6911C07C201/00B82Y5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,445
App. No.
17/658,078
Granted
Oct 14, 2025
Kind
B2
Abstract

Fusogenic compounds, and compositions and methods of use thereof. The fusogenic compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, compounds, compositions and methods are to provide nanoparticles to incorporate or encapsulate active agents, to deliver and distribute the active agents to cells, tissues, organs, and subjects.

Claims (27)

1. A fusogenic compound having Formula VII:

wherein each amphiphile has a structure represented by Formula VIII:

wherein R 1 and R 2 are:

R 1 is CH 2 (CH 2 ) n O(C═O)R 4 , CH 2 (CH 2 ) n NH(C═O)R 4 , CH 2 (CH 2 ) n (C═O)OR 4 , or CH 2 (CH 2 ) n (C═O)NHR 4 ;

R 2 or CH 2 (CH 2 ) m O(C═O)R 5 , CH 2 (CH 2 ) m NH(C═O)R 5 , CH 2 (CH 2 ) m (C═O)OR 5 , or CH 2 (CH 2 ) m (C═O)NHR 5 ;

wherein:

n and m are each independently from 1 to 2;

R 4 and R 5 are independently for each occurrence a C(12-20) alkyl group or a C(12-20) alkenyl group;

wherein each AA a is independently an amino acid of the following structure, and any stereoisomer thereof:

wherein the linker has a structure:

wherein Q 1 is selected from the group consisting of branched or unbranched C(2-8)alkandiyl, branched or unbranched C(2-8)alkenediyl, branched or unbranched C(2-8)alkynediyl,

wherein Q 2 is

wherein Q 3 is

wherein X is selected from the group consisting of —O—, —S—, and —NH—;

n and p are independently for each occurrence 1 to 3;

m is independently 1 to 10; and

r and s are independently for each occurrence 1 to 5.

2. The fusogenic compound of claim 1 , wherein the compound is compound T9:

3. A composition comprising the fusogenic compound of claim 1 , and a pharmaceutically acceptable carrier.

4. The composition of claim 3 , wherein the composition comprises nanoparticles or liposomes.

5. A pharmaceutical composition comprising the fusogenic compound of claim 1 , an active agent, and a pharmaceutically acceptable carrier.

6. The composition of claim 5 , wherein the fusogenic compound is from 0.01 mol % to 20 mol % of the lipids of the composition.

7. The composition of claim 5 , wherein the composition comprises nanoparticles or liposomes.

8. The composition of claim 5 , wherein the active agent is one or more nucleic acids.

9. The composition of claim 5 , wherein the active agent is one or more DNAs, RNAs, mRNAs, siRNAs, or microRNAs.

10. The composition of claim 5 , wherein the active agent is one or more RNA molecules.

11. The composition of claim 5 , wherein the active agent is selected from one or more RNAi molecules, one or more mRNA molecules, and modified forms thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2024
From: TSANG, KWOK YIN; MAJETI, BHARAT; GAUDETTE, JOHN A.; ADAMI, ROGER C.; BAI, HAO; YING, WENBIN
To: NITTO DENKO CORPORATION
Reel/Frame 069150/0043 →
Continuity (3)
Division 16182571 · Nov 6, 2018
Provisional Application 62582252 · Nov 6, 2017
Related Publication 20220233445A1 · Jul 28, 2022
References Cited (46)
US 20030176641A1 · Gokel et al. · 2003 [cited by applicant]
US 20110223257A1 · Zhao et al. · 2011 [cited by applicant]
US 20130022665A1 · Niitsu et al. · 2013 [cited by applicant]
US 20130115274A1 · Knopov et al. · 2013 [cited by applicant]
US 20130171127A1 · Niitsu et al. · 2013 [cited by applicant]
US 20130330401A1 · Payne et al. · 2013 [cited by applicant]
CN 1433478A · 2003 [cited by applicant]
CN 103857654A · 2014 [cited by applicant]
CN 107108686A · 2017 [cited by applicant]
EA 201490847A1 · 2014 [cited by applicant]
EA 026374B1 · 2017 [cited by applicant]
EP 2069500B1 · 2014 [cited by applicant]
EP 2998289A1 · 2016 [cited by applicant]
EP 4393511A1 · 2024 [cited by applicant]
RU 2015119409A · 2017 [cited by applicant]
RU 2615143C2 · 2017 [cited by applicant]
WO WO1996006097A1 · 1996 [cited by applicant]
WO WO2001049324A2 · 2001 [cited by applicant]
WO WO2005026372 · 2005 [cited by applicant]
WO WO2011076807A2 · 2011 [cited by applicant]
WO WO2011119852A1 · 2011 [cited by applicant]
WO WO2012170952A2 · 2012 [cited by applicant]
WO WO2013063468A1 · 2013 [cited by applicant]
WO WO2014076195A1 · 2014 [cited by applicant]
WO WO2016106405A1 · 2016 [cited by applicant]
WO WO2024012272A1 · 2024 [cited by applicant]
Dyson et al., “May's Chemistry of Synthetic Drugs”, MIR Publishers, 5 [cited by applicant]
Office Action issued in Russian Application No. 2020117606, dated Apr. 22, 2022. [cited by applicant]
Pokrovsky. “Medicinal Products”, Popular Medical Encyclopedia, 4 [cited by applicant]
Office Action issued in Brazilian Patent Application No. BR112020008451-4, dated Jul. 28, 2022. [cited by applicant]
Gao et al., “Amphiphilic dendritic peptides: Synthesis and behavior as an organogelator and liquid crystal”, Beilstein Journal of Organic Chemistry, vol. 7, pp. 198-203 (2011). [cited by applicant]
Gennaro A. R., [cited by applicant]
Greene and Wuts, [Eds.] [cited by applicant]
Hermanson Greg T., [cited by applicant]
International Search Report and Written Opinion dated Feb. 4, 2019 in corresponding PCT/US2018/059504, filed Nov. 6, 2018 in 7 pages. [cited by applicant]
International Preliminary Report on Patentability issued in International Application No. PCT/US2018/059504, issued on May 12, 2020. [cited by applicant]
Invitation pursuant to Rule 63(1) EPC, issued in EP Application No. 18872775.4, dated Jul. 1, 2021. [cited by applicant]
Office Action issued in Indian Application No. 202017020619, dated Nov. 30, 2021. [cited by applicant]
Supplementary European Search Report issued in EP Application No. 18872775.4, dated Oct. 29, 2021. [cited by applicant]
Office Action dated Jun. 7, 2024, issued in Australian Application No. 2023202793, filed May 4, 2023. [cited by applicant]
Office Action issued in corresponding Australian Patent Application No. 2018359904, dated Aug. 19, 2022. [cited by applicant]
Hearing Notice dated Oct. 5, 2023 issued in Indian Application No. 202017020619, filed May 15, 2020. [cited by applicant]
Li et al., “Research Progress of Membrane Fusogenic Liposomes as Vaccine Carriers” Chinese Pharmaceutical Journal (2003) 38(10):1-8. [cited by applicant]
Office Action issued in Chinese Application No. 201880071515.7, dated Nov. 23, 2022. [cited by applicant]
Office Action issued in Japanese Patent Application No. 2020-524544, dated Nov. 8, 2022. [cited by applicant]
Hearing Notice dated Sep. 6, 2023, in Indian Application No. 202017020619, filed May 15, 2020. [cited by applicant]